Original ArticlesEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
Under an Elsevier user license
open archive
Key Words
Lung cancer
Adenocarcinoma
Epidermal growth factor receptor
EGFR mutations
Tyrosine kinase inhibitor
Cited by (0)
This study was presented in part at the ESMO 2014 Congress, September 26–30, 2014, Madrid, Spain.
Disclosure: Chao-Hua Chiu and Jin-Yuan Shih received honorarium from AstraZeneca, Boehringer Ingelheim, and Roche. Chun-Ming Tsai received honorarium from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, and Roche. James Chih-Hsin Yang received consultancy from AstraZeneca, Boehringer Ingelheim, Clovis, Eli Lilly, Merk, MSD, Novartis, Takeda, and Roche and grants from Boehringer Ingelheim. The other authors declare no conflict of interest.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.